Jiangsu Hengrui Medicine
600276.SS
#471
Rank
$35.69 B
Marketcap
$5.60
Share price
2.22%
Change (1 day)
-31.71%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

Earnings for Jiangsu Hengrui Medicine (600276.SS)

Earnings in 2022 (TTM): $0.48 B

According to Jiangsu Hengrui Medicine 's latest financial reports the company's current earnings (TTM) are $0.48 B. In 2021 the company made an earning of $0.68 B a decrease over its 2020 earnings that were of $1.04 B.The earnings displayed on this page is the company's Pretax Income.

Earnings history for Jiangsu Hengrui Medicine from 2002 to 2022

Annual earnings

Year Earnings Change
2022 (TTM)$0.48 B-28.96%
2021$0.68 B-34.14%
2020$1.04 B15.95%
2019$0.89 B33.03%
2018$0.67 B20.89%
2017$0.55 B23.89%
2016$0.45 B11.2%
2015$0.40 B39.5%
2014$0.29 B20.61%
2013$0.24 B11.46%
2012$0.21 B29.7%
2011$0.16 B31.16%
2010$0.12 B27.92%
2009$99.45 M5.8%
2008$93.99 M79.95%
2007$52.23 M39.5%
2006$37.44 M31.63%
2005$28.44 M34.07%
2004$21.21 M3.32%
2003$20.53 M38.06%
2002$14.87 M